Characterization of two transcriptomic subtypes of marker-null large cell carcinoma of the lung suggests different origin and potential new therapeutic perspectives
In conclusion, our study split the histological marker-null LCC into two different transcriptomic entities, withPOU2F3,FOXI1, andAIM2 genes as differential expression markers that might be probed by immunohistochemistry for the differential diagnosis between Pure-LCC and ADLike-LCC. Finally, the identification of several signatures linked to replication stress in Pure-LCC and inflammasome complex in ADLike-LCC could be useful for designing new potential therapeutic approaches for these subtypes.
Source: Virchows Archiv - Category: Pathology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | Genetics | Lung Cancer | Pathology | Rare Diseases | Skin Cancer | Squamous Cell Carcinoma | Study | Undifferentiated Carcinoma